We are currently recruiting for the following clinical trials:

Prothena PRX012-102: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of PRX012 in Subjects with Alzheimer’s Disease.

Prothena PRX012-103: Open-Label Extension Study of PRX012 in Subjects with Alzheimer’s Disease Who Were Enrolled in Study PRX012-101 or PRX012-102.

Cognito CA-0011: A Randomized, Double-blind, Sham-controlled, Adaptive- Design Pivotal Study of Sensory Stimulation in Subjects with Alzheimer’s Disease.

Suven CTP3S1502HT6: A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride.

Cognito CA-0015 Open Label Extension to a Randomized Double Blind Sham Controlled, Adaptive-Design Pivotal Study of Sensory Stimulation in Subjects with Alzheimer’s Disease.

Bristol-Myers Squibb: PROTOCOL CN0080003  A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease. (TargetTau-1)

ADEPT-3 CN0120056  KAR 033 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimer’s Disease Dementia.

ProMis A Phase 1b, Double-Blind, Placebo Controlled, Multiple Ascending Dose of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Preliminary Efficacy of PMN310 in Patients With Early Alzheimer’s Disease.

More Studies Being Added Soon!

= Trial is Active and Recruiting